Abstract
Introduction: Triple-negative breast cancer (TNBC) is a highly heterogeneous tumor associated with poor prognosis and variable responses to treatment. Despite the limitations of currently available approaches for disease assessment, liquid biopsy and tumor biomarkers have emerged as promising tools for investigating molecular alterations associated with TNBC. In this context, the identification of candidate proteins and their assessment in tumor samples may provide insights into tumor biology and support the development of novel biomarkers for future clinical applications. Aim: The aim of this study was to explore candidate proteins identified by extracellular vesicle (EV) proteomic analysis and subsequently assess their expression in TNBC tumors by immunohistochemistry. Methods: Proteomic analysis of EVs derived from the blood plasma of patients with TNBC in remission and with tumor recurrence was performed as an exploratory approach to identify candidate proteins associated with recurrence. Subsequently, tumor samples from an independent cohort were evaluated by immunohistochemistry to assess the expression of the selected proteins and explore their associations with survival, histological grade, and clinical staging. The data were analyzed using the Kolmogorov–Smirnov test, Student’s t-test, ANOVA with Tukey’s post hoc test, ROC curve analysis, and Pearson and Spearman correlations, with statistical significance set at p ≤ 0.05. Results: Exploratory EV proteomic analysis identified PSMB4 and LDHA as candidate proteins detected in the recurrence group. In the independent tumor cohort, higher PSMB4 histoscore was associated with advanced clinical staging among patients in remission. LDHA expression showed discriminatory potential between TNBC and benign breast tumors, while higher LDHA expression was associated with shorter survival among patients with recurrent disease. These findings support the expression of the candidate proteins in breast tumors but do not establish their value as circulating biomarkers of recurrence. Conclusions: PSMB4 and LDHA were identified as candidate proteins through exploratory EV proteomic analysis and were subsequently assessed for expression in breast tumors by immunohistochemistry. The findings provide evidence of their expression in the tumor compartment and support further investigation of their biological and clinical relevance. However, the present study does not establish PSMB4 or LDHA as validated biomarkers of recurrence, prognosis, or diagnosis. Further studies using larger, independently defined cohorts and direct assessment of these proteins in circulating EVs are required to determine their potential clinical applicability.